Interferon-induced depression in hepatitis C: An update

被引:24
|
作者
Keefe B. [1 ]
机构
[1] Department of Psychiatry and Behavioral Sciences, University of South Florida, Tampa, FL 33613
关键词
Depressive Symptom; Chronic Hepatitis; Paroxetine; Major Depressive Disorder; Sustained Viral Response;
D O I
10.1007/s11920-007-0028-4
中图分类号
学科分类号
摘要
Hepatitis C is a global epidemic, and its costs in both lives and health care expenditures continue to rise. The only approved treatment for this disease, interferon-alpha (IFN), causes treatment-emergent depression in more than one quarter of all patients who take it. Newer preparations of IFN have been developed to increase its antiviral efficacy, but the incidence of treatment-emergent depression has not decreased. The data on the epidemiology and risk factors for interferon-induced depression are reviewed in an effort to delineate its standing as a unique psychiatric disorder. In addition, evidence-based treatment approaches are outlined, including the potential efficacy of preinterferon prophylactic treatment with antidepressants. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:255 / 261
页数:6
相关论文
共 50 条
  • [41] Chronic hepatitis C: Treatment of pegylated interferon/ribavirin nonresponders
    Shiffman M.L.
    Current Hepatitis Reports, 2006, 5 (3) : 114 - 120
  • [42] HIV and depression: 2008 Review and update
    Rabkin J.G.
    Current HIV/AIDS Reports, 2008, 5 (4) : 163 - 171
  • [43] Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review and meta-analysis
    Ehret, M.
    Sobieraj, D. M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (02) : 255 - 261
  • [44] Hepatitis G virus infection in chronic hepatitis C: Frequency, features and response to interferon therapy
    Saiz, JC
    Ampurdanes, S
    Olmedo, E
    LopezLabrador, FX
    Forns, X
    Guilera, M
    Tassies, D
    Costa, J
    SanchezTapias, JM
    deAnta, MTJ
    Rodes, J
    JOURNAL OF HEPATOLOGY, 1997, 26 (04) : 787 - 793
  • [45] Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy
    Inoue, M
    Ohhira, M
    Ohtake, T
    Matsumoto, A
    Kawashima, T
    Hasebe, C
    Ono, M
    Kohgo, Y
    HEPATO-GASTROENTEROLOGY, 1999, 46 (28) : 2554 - 2560
  • [46] Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a-Induced Depression in Hepatitis C: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Diez-Quevedo, Crisanto
    Masnou, Helena
    Planas, Ramon
    Castellvi, Pere
    Gimenez, Dolors
    Morillas, Rosa M.
    Martin-Santos, Rocio
    Navines, Ricard
    Sola, Ricard
    Giner, Pilar
    Ardevol, Merce
    Costa, Joan
    Diago, Moises
    Pretel, Juan
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (04) : 522 - 528
  • [47] Interferon therapy of chronic hepatitis C in HIV-infected patients
    Paesa, CR
    Garces, PA
    Catalan, AP
    Lazcano, IH
    Errasti, JMA
    REVISTA CLINICA ESPANOLA, 1998, 198 (04): : 221 - 225
  • [48] Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness
    Wong, JB
    ACTA GASTRO-ENTEROLOGICA BELGICA, 1998, 61 (02): : 238 - 242
  • [49] Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin
    Overbeck, Kathrin
    Genne, Daniel
    Golay, Alain
    Negro, Francesco
    JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 295 - 298
  • [50] Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α
    Furlanut, Mario
    Soardo, Giorgio
    Donnini, Debora
    Sechi, Leonardo
    Franceschi, Loretta
    CLINICAL PHARMACOKINETICS, 2010, 49 (11) : 767 - 772